Professor Ljubić’s team recently published an original method for ovarian rejuvenation — DSA (Dual Stem Cell Activation of the Ovary) — in the journal Investigations in Gynecology Research & Women’s Health: DSA – Dual stem cell ovarian activation.
This study explores the potential of dual-double stem cell therapy, which combines mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), as a revolutionary approach to treating ovarian decline, premature ovarian insufficiency (POI), and induced ovarian failure. The synergy between MSCs and HSCs enhances tissue regeneration far beyond what each cell type can achieve individually, offering hope to women facing fertility challenges.
Preclinical and clinical studies have shown promising results, including the restoration of ovarian function, normalization of hormone levels, and even successful pregnancies. This therapy also aligns with the principles of personalized medicine, enabling customized treatments that take into account individual patient variability, thereby increasing treatment effectiveness and reducing side effects.
However, with potential benefits come certain risks. The use of autologous (self-derived) non-expanded stem cells is considered a safe method, but there are challenges related to cell quality and potency. Ethical considerations also play a crucial role, emphasizing the need for informed consent, transparent clinical trials, and regulatory oversight to prevent misuse.
Looking to the future, large-scale clinical trials and the development of standardized protocols are essential to ensure the consistency of therapy and long-term safety. This therapy has the potential to significantly advance reproductive medicine, offering new possibilities for women with ovarian insufficiency.
izvor: Revolutionizing Ovarian Regeneration: The Promise and Perils of Dual-Double Stem Cell Therapy